WHO Pathogen Sharing Talks Clash With America First Health Strategy

Avatar photo

ByRachel Vaughn

September 20, 2026

UN negotiators in Geneva are pushing a new pathogen-sharing system as the Trump administration bypasses multilateralism with $16 billion in bilateral health pacts across Africa.

Negotiations at the World Health Organization in Geneva reached a critical juncture this week as member states advanced the Pathogen Access and Benefit-Sharing (PABS) system. This annex to the 2025 WHO Pandemic Agreement seeks to codify a global exchange where developing nations provide biological samples of emerging viruses in exchange for guaranteed access to vaccines and diagnostics. WHO Director-General Tedros Adhanom Ghebreyesus has positioned the completion of these PABS talks as a mandatory prerequisite for the full ratification and implementation of the global pandemic treaty, urging member states to finalize the framework to ensure no region is left behind in the next crisis.

While Geneva focuses on centralized multilateralism, the U.S. executive branch is aggressively implementing an alternative model that prioritizes national sovereignty and market-driven outcomes. The Trump administration’s new “America First Global Health Strategy” has already secured 13 bilateral health pacts across Africa valued at approximately $16 billion. These agreements represent a significant departure from traditional USAID and WHO-centric aid, shifting cooperation away from international bureaucracies toward direct deals that explicitly favor U.S. pharmaceutical and medical firms. The strategy requires partner governments to increase their own domestic health spending, emphasizing fiscal transparency and reducing long-term dependency on foreign subsidies.

This shift in American policy comes as Africa faces a complex and deteriorating landscape of concurrent health emergencies. The WHO reports that Africa accounted for approximately 75% of global mpox cases in July 2026. Between July 6 and August 16, 11 African countries recorded 1,153 confirmed cases and seven deaths. Madagascar’s outbreak has been described as the largest mpox event globally since December 2025, prompting the WHO to treat the situation as a graded health emergency with standing recommendations now extended through August 2027. The regional burden is further strained by the Ebola epidemic in the Democratic Republic of Congo, which officials warn is far from over. Despite a decline in transmission in the worst-hit Ituri province, the virus has spread to a seventh province, and strengthened surveillance is expected to drive reported case numbers even higher.

In response to these fragmented crises, the WHO Regional Office for Africa recently launched a Regional Health Data Hub. This digital platform aims to integrate data from all 47 member states into a single interface for real-time intelligence on outbreaks and health systems. However, the success of such a hub relies on the very pathogen-sharing protocols currently being debated in Geneva. For American taxpayers and policymakers, the tension between the WHO’s PABS system and the U.S. bilateral approach raises fundamental questions regarding intellectual property. The PABS framework often implies a degree of mandatory technology transfer and “equitable access” mandates that critics argue could undermine the R&D incentives of the American private sector.

By contrast, the new U.S. bilateral pacts leverage American industrial strength to address HIV, tuberculosis, and malaria, ensuring that U.S. capital is tied to measurable outcomes and national interests rather than opaque global funds. As the WHO AFRO reports on ongoing cross-border risks of Ebola Bundibugyo virus disease between the DRC and Uganda, the debate over who controls health data and who sets the terms for medical intervention will intensify. The American stake is clear: while infectious diseases do not respect borders, the mechanisms used to fight them—whether through UN-led mandates or sovereign bilateral contracts—will determine the efficiency and accountability of global health spending for the next decade.

Leave a Reply

Your email address will not be published. Required fields are marked *